The vasoconstrictor activity of angiotensin II was originally considered to be due to a direct effect on vascular smooth muscle (1, 2) . Subsequently, it has been suggested that the sympathetic nervous system participates in the vascular response to angiotensin II (3) (4) (5) . After acute denervation of the limb, the reactivity of the limb vasculature to angiotensin II is reduced in the rat (3) and dog (4) . Bickerton and Buckley (5) have described two elements in the pressor response to angiotensin II: a centrally mediated effect, due to stimulation of central autonomic nervous structures, and a peripheral action on the vascular smooth muscle.
Angiotensin II is not only influenced in its vascular activity by the autonomic nervous system, but itself will release or enhance the response to stimuli releasing catecholamines. Thus, angiotensin II has been reported to enhance the pressor response to tyramine (6) , to release catecholamines from the adrenal medulla (7) , and to lower the threshold to sympathetic nerve stimulation (8) .
Renal ischemia was observed in this laboratory to alter the renal vascular response to angiotensin II. While examining the role of the nervous system in the production of this effect, renal denervation was observed to produce a loss of the renal vasoconstrictor activity of angiotensin II, similar to that produced by renal ischemia (9) . The present study reports on the role of the nervous system in determining the renal vascular reactivity to angiotensin II. The renal vascular bed was selected for this study because it is the most sensitive of the regional beds tested to the vasoconstrictor effect of angiotensin II (10) . Blockade by autonomic drugs of the renal vasoconstriction produced by angiotensin II was demonstrated. Autonomic blocking agents selected were representative of several classes: ganglionic blockade (hexamethonium), alteration of the release of the neurotransmitter by either central (hydralazine) or peripheral activity (guanethidine and bretylium), depletion of the transmitter (reserpine), and receptor blockade (phentolamine). The capacity of autonomic blocking agents to oppose the effects of angiotensin II was related to the activity of the drug at the neuroeffector site. Those abolished the constriction of the renal vasculature produced by angiotensin II intravenously and reduced the response to intra-arterial (ia) angiotensin II. Ten minutes elapsed between, the left and right panels. BP = blood pressure. mined by earlier work as an appropriate interval (9) . c) The observations were confined to the first 90 minutes after having set up the preparation, during which no appreciable time trend was observed (9, 11). d) The renal vascular response to angiotensin II when altered was then compared to levarterenol or epinephrine to exclude the development of vascular refractoriness.
The results were expressed as the maximal change in renal blood flow, mean aortic blood pressure, and calculated vascular resistance elicited by the stimulus. Vascular resistances for the experimental period were determined by dividing the mean aortic blood pressure by the value expressed in milliliters per minute, representing the maximal change in renal blood flow produced by the stimulus. Statistical analyses were made on paired analyses of control and experimental values of the maximal change in renal blood flow and simultaneous blood pressure after application of the stimulus (12) .
Results

Acute renal denervation
In five experiments, acute renal denervation resulted in a loss of the renal vasoconstrictor activity of angiotensin II (0.1 ug per kg) administered intravenously (Table I and Figure 1 ). After acute renal denervation, intravenous administration of 0.1 ,ug per kg of angiotensin II increased renal blood flow in all cases (20 ml per minute, mean of five experiments), whereas the same dose of angiotensin II before denervation always resulted in a reduction of renal blood flow (-42 ml per minute) ( Table I) . After denervation, even a fivefold increase in the amount of intravenous angiotensin II failed to constrict the renal blood vessels ( Figure 1 ). The mean change of renal blood flow elicited by intravenous levarterenol (1 ,Mg per kg) before and after renal denervation, of -76 and -80 ml per minute, respectively, did not differ significantly (Table I) .
In all experiments in which the kidney was denervated, angiotensin II ( Figure 1 ) administered into the renal artery (0.01 ug per kg) continued to elicit renal vasoconstriction (Table I and Figure 1 ). In Figure 2 the effect of angiotensin II upon the renal blood flows measured simultaneously is shown after denervation of one kidney. Under these conditions, angiotensin II elicited a differential effect on renal blood flows; the blood flow to the denervated kidney increased in response to intravenous angiotensin II, whereas vasoconstriction occurred simultaneously in the innervated kidney.
Spinal cord section
In four experiments, nervous activity was modified by interrupting the autonomic nerve supply at the level of the spinal cord (Table II) . The cervical cord was sectioned immediately after recording control observations of the response of the renal vasculature to angiotensin II. After cord section, elimination of the renal vasoconstrictor effect of angiotensin II administered intravenously was noted.
After cord section, angiotensin II (0.1 jug per kg) administered intravenously increased the renal blood flow by 29 ml per minute (mean of four experiments), whereas before cord section a reduction of 88 ml per minute (mean of four experiments) was recorded (p < 0.01; Table II ). The decreased reactivity of the renal vasculature to angiotensin II produced by cord section was not observed for catecholamines. An epinephrine infusion (4 Mg per kg per minute) after cord section resulted in cessation of the renal blood flow. 
Autonomic blocking agents
The effect of acute renal denervation and cord section on the renal vascular response to angiotensin II prompted the use of drugs that modify autonomic nervous activity. The selection of autonomic blocking agents was determined by their possessing major blocking activity at different sites, either prejunctionally, along the autonomic nerve and its central connections, or at the sympathetic receptor (a) that mediates renal vasoconstriction. Phentolamine was used to block the a receptors. The following drugs were used to in- (Figures 3 and 4 , Table IV ).
In Figure 3 , the vasoconstrictor activity of angiotensin II and levarterenol after drug intervention is expressed in terms of their per cent change from control values. Thus before phentolamine, angiotensin II administered intravenously increased renal vascular resistance by 117% and 105%o; after phentolamine a 160%o and 81% increase, respectively, in renal vascular resistance was produced by angiotensin II. The differences (Figure 3 ) of + 37%o and -23%o between the per cent increase of renal vascular resistance angiotensin II produced before and after drug intervention were not significant. To be significant (p < 0.05) a greater than 62%o reduction in the renal vasoconstrictor effect of angiotensin II or levarterenol, after the administration of the blocking drug, was required (Symbols falling below the broken line in Figure 3 represent significant reductions by the blocking drug of the renal vasoconstriction produced by the pressor agent). As expected, phentolamine (0.1 mg per kg, intravenously) in two experiments did block the renal vasoconstriction produced by levarterenol (Figure 3) , whereas the renal vascular effects of levarterenol were not reduced by hexamethonium. In four dogs that had received hexamethonium (Table IV), 0.1 ug per kg of angiotensin II intrave- Figure 5 ), whereas the renal vascular effects of catecholamines were unimpaired. This effect was rapid in onset (within 20 seconds of guanethidine administration, intravenously), was reversed by tyramine, and was more effective than acute renal denervation. Thus acute renal denervation did not abolish the renal vasoconstriction elicited by angiotensin II administered into the renal artery (Table  I) , whereas guanethidine (5 mg intra-arterially or 5 to 10 mg per kg intravenously) eliminated or markedly reduced the renal vascular activity of angiotensin II administered intra-arterially as well ( Figure 6 ). The blockade of the vascular activity of angiotensin II by guanethidine was unrelated to the degree of pre-existing vascular tone, for it was seen at control blood pressures as disparate as 45 mm Hg (posthexamethonium) and 150 mm Hg (Table III) . The pressor effect of angiotensin II administered intravenously was not eliminated by guanethidine.
In three animals each, bretylium (5 mg per kg) and hydralazine (2 mg per kg) also opposed the renal vascular activity of angiotensin IT (Figure   3 ), for the drug-induced reduction in the renal vascular resistance produced by angiotensin II was in each case greater than 62%o of control (p < 0.05). The renal vascular effect of levarterenol (1 ug per kg) was not reduced significantly by either hydralazine or bretylium (Figure 3 ).
Tyramine and renal vascular reactivity. The ability of guanethidine or bretylium to abolish the response to angiotensin II administered intra-arterially was compromised by previous administration of tyramine. The administration of tyramine (100 to 500 ,g per kg) restored the renal vascular activity of angiotensin II after that activity had been blocked by guanethidine ( Figure 6 Figure 7) the sympathetic postganglionic fiber (bretylium ted dog, ex-and guanethidine) (14) or by agents that alter iedjtio, ef sympathetic activity by a central action (hydralainjections do zine) (15 (23) . With these qualifications in mind, a tentative construction of the relationship between angiotensin II and the autonomic nervous system will be attempted. The effects of acute renal denervation upon the renal vascular activity of angiotensin II suggested at least two elements in the renal vascular response. After renal denervation, the renal vascular effect of angiotensin II administered intravenously was eliminated, whereas renal intra-arterial injection of angiotensin II continued to elicit renal vasoconstriction. These observations agree with those of Laverty (3) and Zimmerman (4) . Laverty demonstrated that the vasoconstriction of the rat hind limb elicited by intravenous angiotensin II was immediately abolished by denervation of the limb. Zimmerman showed in the dog that after acute sympathectomy of the hindquarter, the vasoconstrictor response to intra-arterial administration of angiotensin II was reduced. A bimodal mechanism of the action of angiotensin II, one nerve mediated and the other direct, has been postulated by Benelli, Della Bella, and Gandini (8) . In cross-perfusion experiments in dogs, Bickerton and Buckley (5) described a central hypertensive effect of angiotensin II that was blocked peripherally by an adrenergic blocking agent, piperoxan. In the present experiments, the effects of cervical cord transection upon the renal vascular activity of angiotensin II administered intravenously suggest the importance of central nervous activity in the fully developed renal vascular response to angiotensin II.
The failure of hexamethonium to alter the renal vascular response to angiotensin II would appear to exclude a central nervous mechanism in the renal vascular response to angiotensin II administered intravenously. However, hexamethonium has been reported to be ineffective in the blockade of the pressor response to some sympathetic ganglionic stimulants, whereas atropine will block this pressor response (24) . Hertting, Potter, and Axelrod showed that hexamethonium failed to reduce, or only slightly reduced, the spontaneous release of levarterenol-3H from the rat heart, which release is an index of transmission of impulses in postganglionic fibers (16) . In the same preparation, on the other hand, bretylium reduced the release of levarterenol-3H, which is consistent with the presumed effect of bretylium on sympathetic nerve transmission and the renal vascular response to angiotensin II. In addition, Robertson and Rubin (18), using an isolated system, showed that hexamethonium did not block the contractile response of the guinea pig ileum to angiotensin II.
The present results suggest that the renal vascular effect of angiotensin II depends in part at least on the presence of catecholamines, for reserpine will reduce or abolish the reactivity of the renal vasculature to angiotensin II. A reduction of the vascular activity of angiotensin II in the hind limb of the dog has been reported after reserpine (25) . In two of the present experiments, a schedule of reserpine administration that might be expected to reduce catecholamines to less than 10% of the control levels (26) failed to reduce the renal vasoconstrictor activity of angiotensin II. In all of the experiments in which reserpine was used, tyramine failed to elicit renal vasoconstriction. This observation confirms the near depletion of catecholamines effected by reserpine, for Crout, Muskus, and Trendelenburg have reported that in isolated guinea pig atria pretreated with reserpine, only 2% of the normal tissue catecholamines was required for tyramine to produce a response (27) . Nicotine, the renal vasoconstrictor activity of which depends on the presence of local catecholamines, had effects similar to angiotensin II. In the four experiments in which the renal vascular effect of angiotensin II was abolished or reduced by reserpine, the renal vascular activity of nicotine was similarly attenuated. Furthermore, administration of angiotensin II directly after nicotine, after the return of renal blood flow to control levels, resulted in reduced vasoconstriction elicited by angiotensin II (Figure 7 ). These results suggest that nicotine and angiotensin II require an identical or similar store of the sympathetic neurotransmitter for their activity. This store is either affected by these agents directly or through a common intermediary of catecholamine release as acetylcholine. A parallel reduction of the effect of nicotine and angiotensin II on the contraction of the isolated ileum of the guinea pig and rabbit after depletion of acetylcholine has been observed by Robertson and Rubin (18) .
Further evidence to support the participation of catecholamines in the renal vascular response to angiotensin II is provided by the effects of tyramine. After blockade of the renal vascular effects of angiotensin II by guanethidine or section of the spinal cord, tyramine restored the reactivity of the renal vasculature to angiotensin II. Tyramine will not restore the renal vascular activity of angiotensin II after depletion of catecholamines by reserpine. Several lines of evidence relating to the effects of tyramine (or other indirect acting sympathomimetic amines) and guanethidine converge on the autonomic nervous mechanism, which releases the sympathetic neurotransmitter. Guanethidine has been reported to block the pressor effect and the development of tension in isolated atria of rats induced by tyramine, in the absence of any significant reduction of tissue catecholamines (28) . Bhagat has suggested that guanethidine and tyramine act on the same store of levarterenol; a competitive antagonism between guanethidine and tyramine was considered probable (22, 29) . Confirmation of this view is afforded by Matsumoto and Horita (30) , who demonstrated that other indirect acting sympathomimetic amines (dexamphetamine and methamphetamine) of which tyramine is the prototype reduce the uptake of guanethidine by rabbit hearts and fulfill the conditions of competitive antagonism. Competitive antagonism between tyramine and guanethidine posits overlapping activities varying in strength. Thus, guanethidine has weak sympathomimetic actions and strong sympathetic nerve blocking activity, whereas the indirect acting sympathomimetic amines have strong sympathomimetic actions and weak sympathetic nerve blocking activity.
Additional confirmation of the close relationship between sympathetic nerve activity and angiotensin II is provided by observations on the augmentation by angiotensin II of the effects of sympathetic nerve stimulation and sympathomimetic agents. Thus, angiotensin II has been demonstrated by McCubbin and Page to augment the pressor effect produced by sympathomimetic agents (tyramine and ephedrine) and those procedures that release levarterenol from sympathetic nerve endings (6). Benelli and associates have shown potentiation by angiotensin II of the contractions of the vas deferens and spleen produced by sympathetic nerve stimulation (8) .
Autonomic blocking agents have been considered to be ineffective in blocking the vasoconstrictor effect of angiotensin II (4, 31) . The pressor response in normal human subjects to angiotensin II was shown by Laurence and Nagle to be unmodified by bretylium or guanethidine (32) . An awareness that the pressor effect of angiotensin II may be related to several actions of angiotensin II, such as release of catecholamines from the adrenal medulla (7) and a positive inotropic effect (33) , should invalidate any conclusions drawn from assuming a direct relationship between the pressor response and vasoconstrictor properties of angiotensin II. Guanethidine has been reported to be effective in treating the hypertension of occlusive renal arterial disease (34) 
